1

2
Chapman Kevin T, Thornberry Nancy A, Bull Herb G, Weidner Jeffrey R, Maccoss Malcolm, Mjalli Adnan M: Peptidyl derivatives as inhibitors of interleukin-1b converting enzyme.. Merck & Co, December 23, 1992: EP0519748-A2 (77 worldwide citation)

Novel peptidyl derivatives of formula I are found to be potent inhibitors of interleukin-1 beta converting enzyme (ICE). Compounds of formula I may be useful in the treatment of inflammatory or immune-based diseases of the lung and airways; central nervous system and surrounding membranes; the eyes ...


3
Mjalli Adnan M M, Gaddam Bapu R, Qabaja Ghassan, Subramanian Govindan, Zhu Jeff, Dankwardt John, Arimilli Murty N, Andrews Robert C, Victory Samuel, Tian Ye E: Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators. Transtech Pharma, Mjalli Adnan M M, Gaddam Bapu R, Qabaja Ghassan, Subramanian Govindan, Zhu Jeff, Dankwardt John, Arimilli Murty N, Andrews Robert C, Victory Samuel, Tian Ye E, CALKINS Charles W, November 3, 2005: WO/2005/103022 (34 worldwide citation)

The present invention provides substituted thiazole and pyrimidine derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and methods of use in treating human or animal disorders. The compounds of the invention can be useful as ...


4

5
Guzel Mustafa, Santhosh Kalpathy Chidambaresw, Mjalli Adnan M M, Andrews Robert Carl, Polisetti Dharma Rao: Amide derivatives as glucokinase activators. Novo Nordisk, August 20, 2003: EP1336607-A1 (25 worldwide citation)

The invention relates to heterocyclic amide derivatives which are used to activate glucokinase e.g. in the treatment of obesity or diabetes.


6
Lau Jesper F, Vedso Per, Kodra Janos Tibor, Murray Anthony, Jeppesen Lone, Ankersen Michael, Subramanian Govindan, Mjalli Adnan M M, Andrews Robert Carl, Polisetti Dharma Rao, Christen Daniel Peter: N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes. Novo Nordisk, May 25, 2005: EP1532980-A1 (23 worldwide citation)

This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is benefical, such as diabetes. The compounds are of the general formula (I) wherein B is and ...


7
Mjalli Adnan M M, Gaddam Bapu, Polisetti Dharma Rao, Kostura Matthew, Guzel Mustafa: Tricyclic compounds as modulators of tnf-α synthesis and as pde4 inhibitors. Mjalli Adnan M M, Gaddam Bapu, Polisetti Dharma Rao, Kostura Matthew, Guzel Mustafa, High Point Pharmaceuticals, SMITH Lyman H, July 30, 2009: WO/2009/094528 (6 worldwide citation)

The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.


8
Mjalli Adnan M M, Webster Jeffrey C, Rothlein Robert, Tian Ye E: Rage fusion proteins and methods of use. Transtech Pharma, Mjalli Adnan M M, Webster Jeffrey C, Rothlein Robert, Tian Ye E, CALKINS Charles W, August 23, 2007: WO/2007/094926 (5 worldwide citation)

Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusio ...


9
Mjalli Adnan M M, Andrews Robert C, Shen Jane M, Rothlein Robert: Rage antagonists as agents to reverse amyloidosis and diseases associated therewith. Transtech Pharma, Mjalli Adnan M M, Andrews Robert C, Shen Jane M, Rothlein Robert, CALKINS Charles W, January 6, 2005: WO/2005/000295 (5 worldwide citation)

Disclosed are RAGE antagonist compounds that have the ability to reverse pre-existing amyloidosis. Treatment with the RAGE antagonist compounds described herein may be used to reduce plaque size and improve cognition for subjects in the later stages of Alzheimer's disease. Additionally, the RAGE ant ...


10
Mjalli Adnan M M, Andrews Robert C, Xie Rongyuan, Yarragunta Ravindra R, Ren Tan: Beta-carbolin derivatives as ptp-inhibitors. Transtech Pharma, Mjalli Adnan M M, Andrews Robert C, Xie Rongyuan, Yarragunta Ravindra R, Ren Tan, ROLLINS Samuel B, April 24, 2003: WO/2003/033496 (2 worldwide citation)

This invention provides compounds of formula (I) which are u seful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases, the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such ...